Ken Fisher
DYN icon

Ken Fisher’s Dyne Therapeutics DYN Stock Holding History

Ken Fisher’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.86M Buy
323,051
+72,986
+29% +$1.26M ﹤0.01% 453
2025
Q4 		$4.89M Buy
+250,065
New +$4.74M ﹤0.01% 469

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Ken Fisher's DYN Position: Q1 2026 in Review

Ken Fisher increased its Dyne Therapeutics (DYN) stake by 29% in Q1 2026, buying an estimated $1.26M and bringing the position to 323,051 shares worth $5.86M. The position accounts for ﹤0.01% of the portfolio, ranked #453.

Ken Fisher first reported a position in DYN in Q4 2025 and has held it in 2 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Ken Fisher held 323,051 shares of Dyne Therapeutics worth $5.86M as of Q1 2026.
  • Ken Fisher bought 72,986 Dyne Therapeutics shares in Q1 2026, an estimated $1.26M.
  • Dyne Therapeutics made up ﹤0.01% of Ken Fisher's portfolio in Q1 2026, its #453 holding.
  • Ken Fisher first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.